A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Cue Biopharma
University of Pittsburgh
Hospices Civils de Lyon
Shanghai Escugen Biotechnology Co., Ltd
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
Aprea Therapeutics
Arbeitsgemeinschaft medikamentoese Tumortherapie
Labcorp Corporation of America Holdings, Inc
Stanford University
Acepodia Biotech, Inc.
Keythera (Suzhou) Pharmaceuticals Co. Ltd
DxTerity Diagnostics
Xencor, Inc.
Five Prime Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Celldex Therapeutics
HiberCell, Inc.
Klus Pharma Inc.
Fate Therapeutics
Xencor, Inc.
Nektar Therapeutics
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
Exact Sciences Corporation
Boryung Pharmaceutical Co., Ltd
Pfizer
MacroGenics
Incyte Corporation
Incyte Corporation
University of Pennsylvania
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Osaka University
City of Hope Medical Center
Eli Lilly and Company
Swiss Cancer Institute
Stanford University
University of Kansas Medical Center
Duke University
GlaxoSmithKline
Roswell Park Cancer Institute
Amgen
Santa Maria Biotherapeutics